Phase 2 study evaluating PPS efficacy and safety in MPS VI
Source: Giugliani R, et al
February 24, 2023
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.